Association between Vaccination and Persistent Covid-19-Related Symptoms Among Patients with Mild Omicron Infection: A Prospective Cohort Study

Background: While COVID-19 vaccination has been shown to reduce the risk of severe illness, its impact on the occurrence of persistent symptoms in patients with mild Omicron infection remains uncertain. Our objective was to investigate whether COVID-19 vaccination reduces the occurrence of persistent COVID-19-related symptoms 3 months after mild Omicron infection. Methods: Multicenter prospective cohort study was conducted in Brazil between January 2022 and June 2023 when Omicron was predominant. Participants ≥18 years seeking outpatient care for symptomatic SARS-CoV-2 infection were included. The primary outcome was any persistent symptoms at 3 months. Secondary outcomes were organ system-specific persistent symptoms and the EQ-5D-3L utility score. Results: 1,067 patients were enrolled (median age, 39 years), of which 914 (871 completely vaccinated and 43 unvaccinated or incompletely vaccinated). The occurrence of persistent COVID-19-related symptoms at 3 months was 41.6% (n=362) among completely vaccinated and 44.2% (n=19) among unvaccinated or incompletely vaccinated patients (adjusted risk ratio [aRR], 0.87; 95% confidence interval [CI], 0.61-1.23; p=0.43). Complete vaccination was associated with lower occurrence of mental health symptoms (aRR, 0.44; 95% CI, 0.24-0.81; p=0.01). No differences were found in the occurrence of persistent symptoms in other specific domains, nor in EQ-5D-3L utility scores. Conclusions: This study was not able to identify a statistically significant protection of   complete COVID-19 vaccination against any persistent symptoms at 3 months. Nevertheless, complete vaccination was associated with a lower occurrence of persistent mental health symptoms.